2
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Irreversible Antagonism of Beta-Adrenoceptors with Para-Amino-Benzyl-Carazolol Provides Further Evidence for an Atypical Rat Adipocyte Beta-Adrenoceptor

&
Pages 21-35 | Published online: 26 Sep 2008
 

Abstract

Rat adipocytes possess typical beta1 adrenoceptors that can be identified by 125I-cyanopindolol binding but the receptor mediating isoprenaline adenylate cyclase activation possesses properties quite unlike beta1 or beta2 receptors. Separation of these sites has been attempted using the photoaffinity antagonist para-amino-benzyl-carazolol. Preincubation of rat reticulocyte and adipocyte membranes with this agent followed by washing induced a concentration-dependent loss of specific 125I-cyanopindolol sites in both tissues, though the maximal loss was apparently greater in the reticulocyte. However, the loss of sites in both tissues induced a different effect on isoprenaline-stimulated adenylate cyclase. In the reticulocyte, the loss of specific sites was accompanied by an equivalent fall in the maximal stimulation of adenylate cyclase. In the adipocyte there were no significant effects of receptor site loss on the isoprenaline dose-response curve. It is suggested that this data supports the concept that an atypical beta-adrenoceptor, with relatively low affinity for many antagonists, mediates catecholamine-stimulated adenylate cyclase (and lipolysis) in the adipocyte.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.